Response matters in light chain amyloidosis, whatever it takes

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (<scp>DVD</scp>) in relapsed/refractory light chain amyloidosis (<scp>AL</scp>) after initial Bortezomib‐based regime2024 · 1 citations
2. 2Management of relapsed/ refractory AL amyloidosis2026
3. 3A real‐life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis2024 · 4 citations
4. 4Prognostic analysis of newly diagnosed systemic light-chain amyloidosis patients treated with daratumumab2025
5. 5Daratumumab Monotherapy versus Bortezomib-Based Regimens in frail patients with Biopsy-Proven Renal AL Amyloidosis2026